Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 plus Abraxane in Metastatic Melanoma
NCT01933061Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Jan 2014
- Primary completion
- Jan 2014
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
Phase 2, randomised, open-label trial of CC-486 in melanoma (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival at 24 months. Planned start Jan 2014; status: withdrawn.
02
Drugs
CC-486
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01933061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933061.